Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GVAX Prime-Boost in Hormone-Refractory Prostate Cancer
NCT00140400Phase 2Completed
- Sponsor
- Cell Genesys
- Start
- May 1999
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics
01
Overview
Phase 2, open-label trial of GVAX pancreatic cancer vaccine in prostate cancer (PCa) (2 arms), sponsored by Cell Genesys. Primary endpoints: Standard Toxicity Evaluation, Changes in PSA and 1 more. Started May 1999; status: completed.
02
Drugs
GVAX pancreatic cancer vaccine
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00140400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00140400.